Unlike heterogeneous
tumor cells, cancer-associated fibroblasts (CAF) are genetically more stable which serve as a reliable target for
tumor immunotherapy. Fibroblast activation
protein (FAP) which is restrictively expressed in
tumor cells and CAF in vivo and plays a prominent role in
tumor initiation, progression, and
metastasis can function as a
tumor rejection
antigen. In the current study, we have constructed artificial FAP(+) stromal cells which mimicked the FAP(+) CAF in vivo. We immunized a
breast cancer mouse model with FAP(+) stromal cells to perform
immunotherapy against FAP(+) cells in the tumor microenvironment. By forced expression of FAP, we have obtained FAP(+) stromal cells whose phenotype was CD11b(+)/CD34(+)/Sca-1(+)/FSP-1(+)/MHC class I(+). Interestingly, proliferation capacity of the fibroblasts was significantly enhanced by FAP. In the
breast cancer-bearing mouse model, vaccination with FAP(+) stromal cells has significantly inhibited the growth of allograft
tumor and reduced lung
metastasis indeed. Depletion of T cell assays has suggested that both CD4(+) and CD8(+) T cells were involved in the
tumor cytotoxic immune response. Furthermore,
tumor tissue from FAP-immunized mice revealed that targeting FAP(+) CAF has induced apoptosis and decreased
collagen type I and CD31 expression in the tumor microenvironment. These results implicated that immunization with FAP(+) stromal cells led to the disruption of the tumor microenvironment. Our study may provide a novel strategy for
immunotherapy of a broad range of
cancer.